Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Phase II Study of Thalidomide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
研究概览
详细说明
OBJECTIVES:
I. Determine the effect of thalidomide on survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
II. Determine clinical response rates following this therapy in these patients. III. Determine the toxic effects of thalidomide in these patients. IV. Determine the effect of thalidomide on tumor angiogenesis in these patients.
OUTLINE:
Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Texas
-
Houston、Texas、美国、77030
- University of Texas - MD Anderson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
- Histologically proven squamous cell carcinoma of the head and neck
- Recurrent disease OR metastatic disease at initial diagnosis or at recurrence
- Initial therapy of surgery and/or radiotherapy, induction chemotherapy, or concurrent chemotherapy and radiotherapy allowed
- No more than one prior regimen of chemotherapy or biologic therapy for metastatic disease
- Recurrence after adjuvant or induction chemotherapy may have received one additional course of chemotherapy or biologic therapy
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Performance status: Zubrod 0-2
- Life expectancy: At least 3 months
- WBC at least 3000/mm3
- Platelet count at least 100,000/mm3
- Hematocrit at least 30%
- Bilirubin no greater than 1.5 times normal
- SGOT/SGPT no greater than 1.5 times normal
- Creatinine no greater than 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile women must use 2 methods of effective contraception, 1 barrier and 1 hormonal, beginning at least 4 weeks before study and continuing during and for 1 month after study
- Men must use effective barrier contraception during and for 1 month after study
- No grade 2 or greater peripheral neuropathy
- No serious infection or other concurrent illness requiring immediate therapy
- Must be able to take oral medications
- No medical or social factors that would interfere with compliance
PRIOR CONCURRENT THERAPY:
- Any number of courses of one regimen of chemotherapy allowed
- No concurrent cytotoxic chemotherapy
- No concurrent radiotherapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Arm I
Patients receive 4-20 capsules of oral thalidomide once daily.
Dose is escalated in individual patients on a weekly basis for the first 5 weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
|
合作者和调查者
调查人员
- 学习椅:Roy S. Herbst, MD, PhD、M.D. Anderson Cancer Center
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- NCI-2012-02299
- MDA-ID-98270
- NCI-T98-0074
- CDR0000067011 (注册表标识符:PDQ (Physician Data Query))
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.